Popular Articles

Phase III Study Showed Lucentis Improved Vision In Patients With Branch Retinal Vein Occlusion
Genentech, Inc. announced today that the Phase III study BRAVO showed Lucentis® (ranibizumab injection) improved vision, as measured by the primary endpoint of mean change from baseline in best-corrected visual acuity at six months, in patients with macular edema due to branch retinal vein occlusion. The safety profile of Lucentis was consistent with previous experience and no new adverse events related to Lucentis were observed in the study. Retinal vein occlusion (RVO) is a common cause of vision loss that occurs when blood flow through a retinal vein becomes blocked, such as by a blood clot.
pharmacy online
Global AIDS Coordinator Goosby Discusses Slowing Spread Of Disease Among Pregnant Women
Eric Goosby, U.S. global AIDS coordinator and administrator of the President"s Emergency Plan for AIDS Relief, said that slowing the spread of HIV among pregnant women is one of his top priorities, the San Francisco Chronicle reports. In an interview with the Chronicle, Goosby said he also plans to focus U.S. global efforts on education and prevention, as well as convincing other nations to increase their involvement in the fight against HIV/AIDS. Although Goosby stressed the importance of indentifying people who could benefit from antiretroviral drugs, he added that "[w]e"re not going to be able to treat ourselves out of the epidemic, and prevention efforts will need to be continued and increased." He continued, "We also need to look for concentration of patients who have a higher probability of HIV infection, such as pregnant women -- getting them tested, getting them on antiretrovirals, which will prevent transmission to the fetus." Goosby estimated that only around 35% of pregnant women who are HIV positive and could benefit from antiretrovirals receive the drugs.Goosby also praised the efforts of PEPFAR, which was established six years ago under former President George W. Bush. However, he said that more work must be done and that the disease is not controlled. Sub-Saharan Africa, where about 23 million people are living with HIV, "is clearly the epicenter on the planet of this epidemic," Goosby said. He also noted that HIV/AIDS has begun to spread more rapidly among certain populations in Russia, Ukraine, China and Southeast Asia (Doyle, San Francisco Chronicle, 6/24).
News of the day
ACOG Issues New Guidelines On Fetal Monitoring To Resolve Inconsistencies In Interpretation
The American College of Obstetrics and Gynecology recently published new guidelines on electronic fetal monitoring in an attempt to increase consistency in the way physicians interpret and act on the results, the New York Times reports. Electronic fetal monitoring, which was introduced in the 1970s, is used during labor for more than 85% of the four million infants born alive in the U.S. annually, the Times reports. According to the Times, use of fetal monitors became standard obstetrical practice before it was known if the benefits outweighed the risks. The new guidelines refine the meaning of various readings from fetal monitors and could help doctors make better decisions about whether to intervene during labor.According to experts, the widespread adoption of fetal monitoring has produced both negative and positive consequences, including significant increases in caesarean deliveries and the use of forceps during vaginal deliveries. Monitoring has not been found to reduce the risk of either cerebral palsy or fetal death resulting from inadequate oxygen to the fetal brain, as it was intended to do. Furthermore, lawyers commonly use monitoring results to support malpractice cases that might have little merit, which in turn has driven rising malpractice insurance costs and prompted some obstetricians to stop delivering infants.The new guidelines divide monitor readings into three categories to help doctors interpret readings more consistently. The old guidelines had two categories -- reassuring and non-reassuring -- and it was up to the obstetrician to determine whether a non-reassuring reading required intervention. Under the new guidelines, the first category applies when tracings of the fetal heart rate are normal and no specific action is required. The second category is for indeterminate tracings that require evaluation, continuous surveillance and re-evaluation. Obstetricians treating patients in this category should consider other clinical factors that could affect the fetus and whether the patient could be safely moved to category one, according to Catherine Spong of the Eunice Kennedy Shriver National Institute of Child Health and Human Development, which produced recommendations on which the guidelines are based. The final category is for abnormal tracings that require immediate evaluation and efforts to reverse the abnormal heart rate. The Times reports that more refinements to the guidelines are expected to be released in 2010 (Brody, New York Times, 7/7).
Mental Health

Roche Launches Complete Detection Kit For Influenza A /H1N1 On LightCycler(R) System

Roche Applied Science announced the availability of a new detection kit for the Influenza A/H1N1 virus. The detection kit is offered for use in life science research. Roche currently is filing to get approval of the local health authorities worldwide for use of the kit in emergency situations. The kit runs on Roche÷´s LightCycler® 480 II, 2.0, and 1.5 systems. It was evaluated with virus positive sample materials and selectively identifies the new Influenza A H1N1 virus. Compared with other detection kits, it features a couple of advantages in regard to efficiency and handling. "The design of the new detection kits benefitted very much from information we got out of our manifold research cooperations. We are glad of our contribution in supplying fast and reliable tools for the detection of Influenza A/H1N1 to the research community," said Manfred Baier, Head of Roche Applied Science. Applied Science offers a variety of platforms that can be used to help identify the Influenza A H1N1 virus, including Nucleic Acid Purification, Real-Time PCR, Microarrays and Sequencing systems. The company is in close contact with various research institutions and test centers worldwide providing assistance in the detection and characterization of Influenza A H1N1 virus. Currently, there is no human vaccine on the market that protects against Influenza A H1N1 infection. Standard therapy for the disease includes treatment with antiviral drugs like Tamiflu or Relenza. For more information on Influenza A H1N1 please visit www.who.int. Roche


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):